In June 2026, global law firm Hogan Lovells announced its advisory role on CatalYm's $150 million (approximately £120 million) Series B venture capital round—a landmark transaction that underscores the resilience and appeal of UK-based life sciences innovation to international investors. For UK founders building in biotech, therapeutics, and health tech, the deal offers timely lessons in structuring high-value funding rounds, navigating cross-border investment, and leveraging specialist legal expertise to unlock growth capital.

This article unpacks the transaction, explores the broader context of UK life sciences funding, and provides actionable guidance for founders preparing for institutional investment.

The CatalYm Round: Scale, Structure, and Significance

CatalYm, a UK-based life sciences company focused on advancing therapeutic discovery and development, secured $150 million in Series B funding—a substantial validation of its technology platform and market opportunity. Hogan Lovells, one of the world's largest law firms with deep expertise in healthcare, pharma, and venture capital transactions, guided the deal through structuring, due diligence, and documentation.

The round size reflects investor appetite for UK-headquartered biotech at scale. According to the British Private Equity & Venture Capital Association (BVCA), UK venture capital deployed £10.8 billion across 2,424 deals in 2023, with life sciences representing one of the fastest-growing sectors by deal value and investor interest. A $150 million Series B is not routine—it signals investor confidence in the team, IP, regulatory pathway, and commercial potential.

For founders, the Hogan Lovells involvement highlights why specialist legal counsel matters in high-stakes rounds. Life sciences deals involve additional complexity: patent strategy, regulatory milestones (FDA, EMA, MHRA approvals), clinical trial oversight, licensing agreements, and often international partnerships. A generalist lawyer can miss material issues; a dedicated health tech and pharma practice identifies and mitigates risk early, accelerating due diligence and closing.

UK Life Sciences Funding Landscape: Context and Opportunity

The CatalYm round lands in a competitive but buoyant UK life sciences ecosystem. Several factors are driving capital into UK-based founders:

  • Government Support: The UK government has committed to positioning the country as a global life sciences leader. The Life Sciences Vision (announced 2021) and subsequent funding pledges through Innovate UK and the Advanced Research and Invention Agency (ARIA) signal sustained policy backing. Founders can access grants, R&D tax relief, and patent box incentives that reduce burn and extend runway.
  • Academic Spillover: UK universities—Oxford, Cambridge, Imperial, UCL, GSK—generate world-class IP and talent. Many founders emerge from academic labs or partner with university research centres, giving them early-stage IP validation and credibility with investors.
  • Regulatory Advantage: MHRA (Medicines and Healthcare products Regulatory Agency) and EMA pathways are well-established. UK membership of the International Council for Harmonisation (ICH) ensures regulatory reciprocity with global markets.
  • Investor Concentration: London and Cambridge host a dense network of life sciences-focused VCs (Longitude Capital, Medicxi, Syncona, etc.), corporate investors (pharma majors with UK R&D hubs), and international syndicates seeking UK exposure.

However, post-2023, funding has become more selective. Investors prioritise proven team execution, clear regulatory milestones, and validated market need. A $150 million Series B typically requires: product-market fit evidence, clinical data (Phase I/II de-risking), experienced management, and a path to profitability or exit within 7-10 years.

The Hogan Lovells advisory on CatalYm illustrates several critical structuring decisions relevant to any UK founder raising international capital:

Entity Structure and Incorporation

Most UK venture-backed companies operate as private companies limited by shares (Companies House registration). For international rounds, founders must decide: remain a UK entity, establish a US subsidiary, or dual-incorporate. Each has tax and governance implications.

A UK parent with a US subsidiary is common for life sciences because:

  • US investors prefer US-registered entities (simpler cap table, familiar corporate law).
  • FDA engagement and clinical trials often require a US presence.
  • Exit optionality (M&A or IPO) benefits from US regulatory and capital market access.

However, UK companies can raise from US VCs directly. The key is clarity: ensure your corporate structure is documented, cap table is clean (no phantom equity, clear option grants), and Articles of Association are VC-friendly (anti-dilution rights, information rights, liquidation preferences).

Funding Round Documentation

Series B rounds typically use a Standard Investment Document (SID), now aligned across the UK and Europe for consistency. Key documents include:

  • Share Purchase Agreement (SPA): Terms, price per share, investor rights (board seats, information rights, anti-dilution), and founder vesting (often 4-year vest, 1-year cliff, to protect investor interest).
  • Shareholders' Agreement: Governance, drag-along rights (forcing minority shareholders to accept acquisition), tag-along rights, and protective provisions (major decisions require investor consent).
  • Term Sheet: Non-binding outline of investment terms, agreed in principle before legal documentation.

For life sciences, additional documents often appear: IP assignment agreements (ensuring all founder and employee IP is assigned to the company), material transfer agreements (with university partners), and regulatory strategy documents (outlining clinical trial planning and regulatory milestones).

Tax Structuring: Enterprise Investment Scheme (EIS) and Seed EIS

UK founders should also consider tax-efficient fundraising paths. The Enterprise Investment Scheme (EIS) allows qualifying UK companies to raise equity from investors who benefit from income tax relief (up to 30% on investment) and capital gains tax deferral. For early-stage or Series A rounds, Seed EIS offers similar benefits with simplified conditions.

By Series B, many companies have exceeded EIS reliefs (£12 million gross assets limit), but founders should confirm tax status with accountants. The tax relief makes equity more attractive to angels and early-stage VCs, reducing pressure to price the round aggressively.

Hogan Lovells' Role: What Law Firm Expertise Delivers in a $150M Deal

Hogan Lovells is consistently ranked in the top tier of legal advisors for life sciences M&A and VC transactions. Its global presence (150+ offices) and sector expertise make it suitable for cross-border rounds. Here's what a firm of this caliber typically provides:

Due Diligence Support

VCs conduct extensive due diligence before committing capital. Legal due diligence covers:

  • IP audit: Patents, trade secrets, licenses, freedom-to-operate searches ensuring CatalYm's technology doesn't infringe third-party rights.
  • Regulatory compliance: Clinical trial protocols, MHRA approvals, product liability insurance, adverse event reporting.
  • Employment and equity: Employee contracts, option pool grants, unvested equity cliffs, any litigation or departing founder disputes.
  • Contracts and partnerships: Supply agreements, customer contracts, university licensing, pharma partnerships (material terms, termination risks).

A $150 million round typically attracts co-investors (often US and European VCs), meaning due diligence documentation must satisfy multiple parties. Hogan Lovells standardizes findings in a data room (secure online repository) indexed for efficient review.

Tax and Regulatory Strategy

Cross-border rounds trigger UK, US, and potentially EU tax considerations. Hogan Lovells advises on:

  • US Securities Act compliance (Regulation D exemptions for accredited investors).
  • UK Listing Authority and FCA requirements if shares are offered to UK retail investors (unlikely in institutional VC, but relevant for SEIS/EIS investors).
  • Transfer pricing (if a US subsidiary is created, intercompany transactions must meet HMRC Transfer Pricing rules).
  • Double-tax treaty provisions (UK-US tax treaty minimises double taxation on dividends, interest, gains).

Governance and Board Structure

Series B rounds typically include investor board seats. Hogan Lovells ensures clean governance: board composition aligns with shareholder base, conflicts of interest are managed, and founder-friendly clauses (board observer rights, information access) are preserved.

Lessons for UK Biotech Founders Raising Institutional Capital

The CatalYm transaction and Hogan Lovells' advisory role offer several takeaways for founders preparing for large VC rounds:

1. Invest in Specialist Legal Counsel Early

Hiring a generalist or startup lawyer for a £120 million round is false economy. By Series B, you need healthcare-focused lawyers who understand FDA/EMA pathway risks, pharma licensing, and institutional investor expectations. Costs (typically £50,000–£200,000+ for full round legal) are material but recoverable through smoother due diligence and faster closing. Start building relationships with specialist firms during Series A; they'll know your business and ID issues proactively.

2. Ensure Robust IP and Patent Strategy

VCs scrutinize IP carefully in life sciences. Ensure: all founder and employee IP is assigned to the company (via employment contracts and equity award documents), patents are filed in key markets (UK, US, EU at minimum), freedom-to-operate searches are current, and any university licensing is clearly documented and non-exclusive where possible. A patent challenge or infringement risk can crater a round.

3. De-Risk the Regulatory Pathway

For therapeutics or medical devices, investors want visibility on regulatory milestones. Engage MHRA or FDA early (pre-clinical meetings) to validate trial design. Document regulatory strategy in fundraising materials. Regulatory approval is the ultimate gating factor for life sciences; showing experienced management and clear milestones dramatically improves investor confidence.

4. Build a Cap Table You're Proud Of

A messy cap table (phantom equity, unclear option grants, founder disputes) will kill a Series B. Audit your cap table before raising: confirm all shares are properly issued, all employee options are documented and vested correctly, and no former founders or employees have claims. Use cap table management software (Pulley, Carta, or similar) to track ownership accurately. Investors will spend weeks auditing this; make it clean.

5. Plan for US Investor Appetite

CatalYm's $150 million round likely includes US VCs (Sequoia, a16z, Lightspeed, etc. have UK interest). US investors expect US-friendly structures, predictable governance, and a clear US go-to-market strategy. If you're raising internationally, assume you'll need a US subsidiary or at least US operational presence. Plan this early; it affects entity structure, tax, and hiring strategy.

UK Government Support and Parallel Funding Pathways

While VC is the headline capital source for a £120 million deal, UK founders should layer in complementary funding to reduce burn and extend runway:

  • Innovate UK grants: Innovate UK offers grants (typically £100k–£5m) for R&D projects with commercial potential. Life sciences companies often secure grants for early-stage clinical trials, biomarker validation, or manufacturing process development. Grants don't dilute equity and can fund parallel workstreams.
  • R&D Tax Relief: R&D tax relief provides a credit or deduction for qualifying R&D spend. For biotech, much development qualifies (trial design, manufacturing optimisation, software for diagnostics). This effectively reduces the burn rate and extends runway.
  • Patent Box: If your company is profitable and generates IP-derived income, the UK patent box reduces corporation tax on IP profits. Less relevant pre-revenue, but valuable post-launch.

The CatalYm round and Hogan Lovells' advisory signal several trends worth monitoring:

Consolidation Around Core Strengths

UK life sciences funding is increasingly concentrated in areas where the UK has genuine competitive advantage: early-stage discovery tech, AI-driven drug discovery, cell and gene therapy, and digital health. CatalYm appears positioned in this space. Conversely, late-stage clinical development (Phase III trials, commercial scale-up) increasingly migrates to US and China, where population, healthcare infrastructure, and pharma infrastructure are more mature.

Rising Scrutiny of Regulatory and Commercial Path

Post-2023, investors are less willing to fund purely scientific breakthroughs without clear commercial pathway or regulatory clarity. A strong team, early data, and a realistic timeline to first approval matter enormously. Founders without clinical or regulatory expertise should hire experienced CMOs (Chief Medical Officers) or Chief Development Officers early to build investor confidence.

Global Investor Syndicates and London's Role

Large rounds (£50m+) are increasingly syndicated globally: US VCs, European growth funds, Asian strategic investors, and UK anchors. London acts as a bridge between US and EU markets. For founders, this means: build relationships with tier-1 VCs across regions, expect longer fundraising (6–9 months for large rounds), and use specialist advisors (law firms, bankers) to coordinate complexity.

ESG and Sustainability Pressure

Life sciences investors increasingly consider ESG factors: diverse founding teams, sustainable manufacturing, equitable access to therapies, and responsible clinical trial design. In due diligence, expect questions on governance, equity metrics, and impact goals. Founders who articulate strong ESG narratives alongside financial returns are more attractive to institutional LPs.

Conclusion: What Hogan Lovells' CatalYm Advisory Tells Us About the Future of UK Life Sciences Fundraising

Hogan Lovells guiding a £120 million venture capital round for a UK life sciences startup is not exceptional—it's a clear signal of maturity and confidence in the UK biotech ecosystem. The transaction demonstrates that ambitious UK founders can access world-class capital and specialist advice to scale transformative technologies.

For founders considering institutional fundraising, the key lessons are clear: invest in specialist legal and regulatory expertise, build a bulletproof cap table and IP position, de-risk the regulatory pathway, and structure for cross-border appeal (US investor expectations, clean governance, scalable operations). The legal, tax, and corporate infrastructure required for a $150 million round is material, but proper planning reduces friction and accelerates closing.

The UK life sciences landscape remains compelling for VCs seeking exposure to innovation-led growth. As government support continues and investor appetite remains strong, the next wave of founders building in therapeutics, diagnostics, and health tech platforms have a genuine opportunity to scale globally—with the right team, capital, and legal guidance behind them.